← Back to all trials
Recruiting
NCT07413757
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Conditions: Non-Small Cell Lung Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 590
Sponsor: AstraZeneca
Location: Research Site Chengdu
Summary
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Eligibility Criteria
Inclusion Criteria:
The following inclusion criteria must be met in order to be enrolled in the stage 1:
Patient:
* Provide informed consent
* 18 years or older
* Diagnosed with stage IV NSCLC
* Currently receiving or previously received 1L EGFR-TKI treatment
* Without communication barrier
* Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter
Physician:
* Provide informed consent
* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
* Holding the title of associate chief physician or higher
The following inclusion criteria must be met in order to be enrolled in the stage 2:
Patient:
* Provide informed consent
* 18 years or older
* Diagnosed with stage IV NSCLC
* Currently receiving or previously received 1L EGFR-TKI treatment
* Without communication barrier
* Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter
Physician:
* Provide informed consent
* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
* Holding the title of attending physician or higher
Exclusion Criteria:
Not applicable.
Source: ClinicalTrials.gov (NCT07413757). StuddyBuddy aggregates publicly available trial information.